Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate

PURPOSE: Motesanib (AMG 706) is a multitargeted anticancer agent with an inhibitory action on the human vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and the cellular stem-cell factor receptor (KIT). The aim of this single-arm phase II clinical study was t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawaki, Akira, Yamada, Yasuhide, Komatsu, Yoshito, Kanda, Tatsuo, Doi, Toshihiko, Koseki, Masato, Baba, Hideo, Sun, Yu-Nien, Murakami, Koji, Nishida, Toshirou
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2009
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2824121/
https://www.ncbi.nlm.nih.gov/pubmed/19690858
http://dx.doi.org/10.1007/s00280-009-1103-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2824121/
https://www.ncbi.nlm.nih.gov/pubmed/19690858
http://dx.doi.org/10.1007/s00280-009-1103-9

Ejemplares similares